Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NMRA Neumora Therapeutics, Inc.

Market Closed 01-23 16:00:00 EST

2.06

-0.04

-1.90%

盘后2.10

+0.04+1.94%

19:42 EST

High2.15	Low2.05	Vol783.39K
Open2.09	D1 Closing2.10	Amplitude4.76%
Mkt Cap350.20M	Tradable Cap177.29M	Total Shares170.00M
T/O1.64M	T/O Rate0.91%	Tradable Shares86.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":2.06,"timestamp":1769202000000,"preClose":2.1,"halted":0,"volume":783394,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.06,"latestTime":"19:42 EST","volume":4468,"amount":9260.2272,"timestamp":1769215377585,"change":0.04,"changeRate":0.019417,"amplitude":0.019417},"delay":0,"changeRate":-0.019047619047619063,"floatShares":86062982,"shares":170000000,"eps":-1.463171,"marketStatus":"Market Closed","change":-0.04,"latestTime":"01-23 16:00:00 EST","open":2.09,"high":2.15,"low":2.05,"amount":1635341.0071338,"amplitude":0.047619,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.463171,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":2.1,"preHourTrading":{"tag":"盘前","latestPrice":2.07,"preClose":2.1,"latestTime":"09:22 EST","volume":13257,"amount":28253.026745999996,"timestamp":1769178146998,"change":-0.03,"changeRate":-0.014286,"amplitude":0.042},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.06,"latestTime":"19:42 EST","volume":4468,"amount":9260.2272,"timestamp":1769215377585,"change":0.04,"changeRate":0.019417,"amplitude":0.019417},"volumeRatio":0.3630210926399341,"impliedVol":0.8328,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/NMRA/tweets","defaultTab":"tweets","newsList":[{"id":"2602510112","title":"Leerink Initiates Neumora Therapeutics at Outperform With $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510112","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510112?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:09","pubTimestamp":1768223363,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) has an average rating of overweight and mean price target of $9.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA"],"gpt_icon":0},{"id":"2602051745","title":"Neumora Therapeutics Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2602051745","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602051745?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:54","pubTimestamp":1768222440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 07:54 ET (12:54 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2602514074","title":"Neumora Therapeutics Unveils Pipeline Advancements in Neuroscience and Metabolic Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514074?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:09","pubTimestamp":1768219770,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc. has released a corporate presentation outlining its current pipeline and leadership team. The company is advancing a range of drug candidates targeting major health disorders, including metabolic, neurodegenerative, and neuropsychiatric diseases. Key programs in development include NMRA-215 and an undisclosed therapy for obesity, NMRA-511 for agitation in Alzheimer’s disease, NMRA-GCASE and NMRA-CK1δ for Parkinson’s disease and ALS, as well as treatments for major depressive disorder and schizophrenia. The leadership team features experienced executives across operations, scientific development, and strategy. The presentation also highlights Neumora’s focus on developing brain-penetrant therapies with the goal of addressing unmet needs in large patient populations. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL981fB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2602516860","title":"Neumora Therapeutics initiated with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2602516860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602516860?lang=en_us&edition=fundamental","pubTime":"2026-01-12 18:25","pubTimestamp":1768213532,"startTime":"0","endTime":"0","summary":"Leerink analyst Marc Goodman initiated coverage of Neumora Therapeutics (NMRA) with an Outperform rating and $8 price target The firm likes the com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-initiated-with-an-outperform-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-initiated-with-an-outperform-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA"],"gpt_icon":0},{"id":"2602591753","title":"U.S. RESEARCH ROUNDUP-American Express, Ameriprise Financial, Mastercard","url":"https://stock-news.laohu8.com/highlight/detail?id=2602591753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602591753?lang=en_us&edition=fundamental","pubTime":"2026-01-12 15:42","pubTimestamp":1768203746,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-American Express, Ameriprise Financial, MastercardJan 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL4N3YD0E7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAR","LU2764263203.CNY","COF","H","DG","MA","MCHP","BFH","AA","FISV","CNO","LU1119994496.HKD","HLT","PYPL","LU2491050154.USD","PARR","JAZZ","EQH","CCI","AD","GPN","LNC","NMRA","ALLY","MDGL","NUE","BA","GL","AFL","LU1548497426.USD","MET","OMF","AXP","CSGP","LU0316494557.USD","AMP","OPRT","AIR","PSX","LU1868837136.USD","CE","BK4585","LU1718418525.SGD","INSM","STZ","MDLN","JXN","CRBG","AMT","CHH"],"gpt_icon":1},{"id":"2601036266","title":"3 Penny Stocks With Market Caps Under $700M","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036266","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601036266?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:05","pubTimestamp":1767870318,"startTime":"0","endTime":"0","summary":"Major U.S. stock indexes have recently pulled back after setting fresh all-time highs, reflecting a complex economic landscape influenced by geopolitical events and fluctuating oil prices. In this climate, investors often seek opportunities in lesser-known areas of the market where potential growth can be found. Penny stocks, despite their somewhat outdated name, represent such an opportunity by offering affordability and potential for growth when backed by strong financials.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/3-penny-stocks-with-market-caps-under-700m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/3-penny-stocks-with-market-caps-under-700m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4531","BK4505","BK4213","PROK","BK4539","BK4551","BK4209","BK4166","BK4007","BK4139","EGY","NAUT","BK4134","BK4121","BK4173","LX","DDL","LU1235295612.USD","CINT","BK4526","BK4579","LCUT","BABB","BK4023","BK4509","LU0049112450.USD","MAPS","BK7023","EGY.AU","WDH","TUYA","LU1046422090.SGD","NMRA","BK4180","BK4113"],"gpt_icon":0},{"id":"2601838854","title":"Mizuho Adjusts Price Target on Neumora Therapeutics to $6 From $5, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601838854","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601838854?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:12","pubTimestamp":1767625958,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) has an average rating of overweight and mean price target of $9.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","NMRA"],"gpt_icon":0},{"id":"2601887937","title":"Neumora Therapeutics Shares Rise 10% After Co Reports Positive Results From Early-Stage Alzheimer’s Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601887937?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:31","pubTimestamp":1767623492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2601460882","title":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive","url":"https://stock-news.laohu8.com/highlight/detail?id=2601460882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601460882?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:14","pubTimestamp":1767622447,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","FIVN","SLB","ALB","EOG","IBM","SCCO","ANET","HAL","LBRT","HL","KBR","OKTA","FTV","INCY","GHRS","BKR","SKYE","SATL","ALT","GOOGL","HCA","DUOL","ALRS","DVN","MBLY","OMC","CDE","AZO","SPIR","SGHT","NEM","RMTI","STX","BKSY","COP","ARDT","EBC","THC","RIOT"],"gpt_icon":1},{"id":"2601886502","title":"BUZZ-U.S. STOCKS ON THE MOVE-Arista Networks, Silver Miners, IBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886502?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:10","pubTimestamp":1767615041,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Arista Networks, Silver Miners, IBMEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANET","BK4532","LU2357305700.SGD","BK4592","LU1223082519.USD","RIOT","RMTI","LU0006306889.USD","LU0731783394.SGD","BK4007","FIVN","LU0061474960.USD","IE00B5TLWC47.USD","LU2458330169.SGD","NEM","SG9999001143.SGD","ALB","LU0511384066.AUD","BK4141","HAL","CDE","LU1974910355.USD","LU1861217088.USD","HL","BK4009","XOM","LU0098860793.USD","SG9999002521.SGD","NMRA","BKR","IBM","LU0868494617.USD","LU0057025933.USD","SLB","IE00BMPRXR70.SGD","LU2458330243.SGD","OMC","IE00BMPRXN33.USD","LU1267930730.SGD","QXO","LU0345774631.USD","LU1883866441.USD","BK4581"],"gpt_icon":1},{"id":"2601883066","title":"Press Release: Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2601883066","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601883066?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:35","pubTimestamp":1767612900,"startTime":"0","endTime":"0","summary":"Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation. KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026. Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model. NMRA-215: Plans to initiate Phase 1 clinical program following class-leading preclinical data. Neumora expects to initiate a clinical program evaluating NMRA-215 monotherapy and combination therapy for the treatment of obesity in the first half of 2026. The Company expects to report weight loss data following treatment wit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","NMRA","BK4081","AD","BK4132","PAM","BK4007"],"gpt_icon":0},{"id":"2601883404","title":"Neumora Therapeutics Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601883404","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601883404?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:30","pubTimestamp":1767612611,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc. has announced positive results from its Phase 1b signal-seeking study of NMRA-511, a selective vasopressin 1a receptor antagonist, in patients with agitation associated with Alzheimer’s disease. The study demonstrated a clinically meaningful reduction of 15.7 points on the mean Cohen-Mansfield Agitation Inventory  total score and showed a favorable safety and tolerability profile, with treatment-emergent adverse events mostly mild to moderate and a low discontinuation rate. The company plans to advance NMRA-511 development by initiating a multiple ascending dose extension study and formulation development for once-daily extended-release dosing in 2026, as well as a Phase 2/3 dose-ranging study. These findings were presented during a company webcast and conference call held on January 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL288hS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4585","IE00B3QW5Z07.USD","BK4588","NMRA","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","BK4007"],"gpt_icon":0},{"id":"2601883452","title":"Neumora Therapeutics Announces Positive Results From Nmra-511 Phase 1B Signal-Seeking Study in Alzheimer’s Disease Agitation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601883452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601883452?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:30","pubTimestamp":1767612600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUAB8QSQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2601883294","title":"Neumora Therapeutics Inc - to Evaluate Higher Doses of Nmra-511 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601883294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601883294?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:30","pubTimestamp":1767612600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUAB8QSQR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2601883215","title":"Neumora Therapeutics Inc - Nmra-511 Shows 15.7 Reduction on Mean Cmai Total Score","url":"https://stock-news.laohu8.com/highlight/detail?id=2601883215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601883215?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:30","pubTimestamp":1767612600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUAB8QSQR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2601588329","title":"Neumora Therapeutics Inc - Nmra-511 Shows Unsurpassed Effect Size in Elevated Anxiety Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601588329?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:30","pubTimestamp":1767612600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUAB8QSQR:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2588177016","title":"Neumora Therapeutics Shares Rise After RBC Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588177016","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588177016?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:56","pubTimestamp":1764618984,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics  shares were up 8% in recent Monday trading after RBC Capital Markets upgraded the company's stock to outperform from sector perform and raised its price target to $7 from $4.Trading volume stood at over 1.8 million, versus the daily average of about 1.5 million.Price: 2.42, Change: +0.18, Percent Change: +8.04","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA"],"gpt_icon":0},{"id":"2588777403","title":"Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777403","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777403?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:45","pubTimestamp":1764614700,"startTime":"0","endTime":"0","summary":"RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49144348/analyst-sees-value-in-neumoras-expanding-obesity-and-metabolic-pipeline","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49144348/analyst-sees-value-in-neumoras-expanding-obesity-and-metabolic-pipeline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["NMRA","BK4007","VTYX"],"gpt_icon":0},{"id":"2588724301","title":"Neumora Therapeutics Raised to Outperform From Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724301","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724301?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:43","pubTimestamp":1764589380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 06:43 ET (11:43 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2588211577","title":"Shares of Neumora Therapeutics up 8% Premarket After RBC Raises to Outperform From Sector Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=2588211577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588211577?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:21","pubTimestamp":1764588101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70M8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neumoratx.com","stockEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.1381},{"period":"3month","weight":-0.2167},{"period":"6month","weight":-0.1234},{"period":"1year","weight":-0.0463},{"period":"ytd","weight":0.1508}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.","exchange":"NASDAQ","name":"Neumora Therapeutics, Inc.","nameEN":"Neumora Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neumora Therapeutics, Inc.(NMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neumora Therapeutics, Inc.,NMRA,Neumora Therapeutics, Inc.股票,Neumora Therapeutics, Inc.股票老虎,Neumora Therapeutics, Inc.股票老虎国际,Neumora Therapeutics, Inc.行情,Neumora Therapeutics, Inc.股票行情,Neumora Therapeutics, Inc.股价,Neumora Therapeutics, Inc.股市,Neumora Therapeutics, Inc.股票价格,Neumora Therapeutics, Inc.股票交易,Neumora Therapeutics, Inc.股票购买,Neumora Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neumora Therapeutics, Inc.(NMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}